Tel: 561-316-3330
Email: mdnewsmagazine@infomeddnews.com
Home Blog Page 26

José Trevejo M.D. Ph.D Appointed Chief Medical Office at Enveda Biosciences

Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today the appointment of José Trevejo M.D. Ph.D., as Chief Medical Officer and Head of Clinical Pipeline Strategy. In this role, Dr. Trevejo will lead the clinical organization and oversee the advancement of Enveda’s robust pipeline that spans multiple therapeutic areas.

Dr. José Trevejo joins Enveda following a string of recent successes, most recently at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of a novel category-creating ophthalmic treatment along with multiple positive Phase 2 readouts. He brings more than fifteen years of leadership and drug development expertise to Enveda, spanning the entire clinical development process from proof-of-concept through approval and early commercialization. Dr. Trevejo has worked across numerous therapeutic areas, including GI, dermatology, ophthalmology, infectious disease, cardiac and metabolic disease as well as immunology.

“We are incredibly excited to welcome Dr. José Trevejo to our leadership team,” said Viswa Colluru, Ph.D., CEO and Founder of Enveda. “His entrepreneurial spirit is further complemented by the operational excellence that he learned from his time at Vertex, Genentech and other successful biopharma companies. His deep background in shepherding novel therapies successfully through clinical trials will be essential to Enveda’s success as we prepare our first two drug candidates for transition into human clinical trials, with many more close behind.”

“It is a huge honor to be joining Enveda at this transformative phase of the company,” says Dr. Trevejo. “Enveda’s approach to identifying new molecules from nature using AI and then adapting them into novel medicines is compelling. However, Enveda’s platform offers more than just a technological breakthrough in identifying novel chemical entities, as the drug candidates in Enveda’s pipeline have the potential to address high impact diseases for patients across a range of therapeutic areas. I believe Enveda’s approach will potentially offer new hope to these patients, and I am excited by the opportunity to contribute to such an innovative company and culture that represents the cutting edge of drug discovery and development.”

José Trevejo M.D., Ph.D. is a physician-scientist and biotechnology executive who has led organizations in the development of high impact medicines spanning multiple therapeutic areas. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology drug. Dr.Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, Jose held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Jose Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.

MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioproc

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business has closed the transaction to acquire Mirus Bio for approximately US$ 600 million (around € 550 million), following regulatory clearances and the fulfillment of other customary closing conditions.

The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. It also reinforces the company’s commitment to supporting customers in advancing cell and gene therapies from preclinical through commercial production. The Life Science business of Merck KGaA, Darmstadt, Germany acquired Mirus Bio from Gamma Biosciences, a life sciences platform established by global investment firm KKR.

“Novel modalities like cell and gene therapies offer tremendous potential for bringing new curative treatments to patients,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “Mirus Bio’s advanced technology, combined with our bioprocessing expertise and broad portfolio, will enable us to deliver integrated solutions across the viral vector value chain and help meet the growing demand for these life-saving therapies.”

Mirus Bio specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®. These reagents play a critical role in the production of viral vector-based gene therapies. The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigma’s upstream portfolio and allows for an integrated viral vector manufacturing offering.

Mirus Bio’s leading transfection reagents further strengthen MilliporeSigma’s existing portfolio. The Life Science business of Merck KGaA, Darmstadt, Germany provides solutions for every step of the viral vector manufacturing process to advance cell and gene therapies from preclinical through commercial production. Its portfolio is one of the broadest in the industry and includes cell lines, cell culture media, process materials like chemicals, buffers and enzymes, as well as systems, filters, hardware and consumables. MilliporeSigma’s expertise covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, the company offers contract testing and comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience supporting cell and gene therapies.

Nexus Children’s Hospital – Dallas Partners with Pediatric Acute Care Associates to Improve Continuity of Care

Nexus Health Systems is pleased to announce a partnership between Nexus Children’s Hospital – Dallas and Pediatric Acute Care Associates of North Texas which will give pediatric patients at Medical City Hospital Dallas access to coordinated step-down care. Led by Dr. Michele Papo, this partnership creates a more continuous experience for those moving from a pediatric intensive care unit (PICU) to Nexus’ transitional care unit.

“We are thrilled to partner with Dr. Papo and Pediatric Acute Care Associates of North Texas to provide a more seamless transition from intensive to transitional care,” said Nexus Children’s Hospital – Dallas CEO Roger Caron. “Dr. Papo and her team have a proven track record of providing exceptional care for medically complex patients. Together, we can ensure they experience a smooth transition from critical care to lower acuity levels of treatment and rehabilitation.”

Located 15 minutes east of the Dallas Medical Center, Nexus Children’s Hospital provides complex post-acute care for infants, children, adolescents and young adults in a state-of-the-art facility. The hospital’s interdisciplinary team creates specialized treatment plans to address debilitating conditions such as brain and spinal cord injuries, neurodevelopmental delays and co-occurring medical, behavioral and mental health needs.

Nexus specializes in providing transitional care for young patients who have stabilized in the PICU but are not yet ready to return home. The partnership with Pediatric Acute Care Associates of North Texas makes it easier for caregivers to identify Nexus as an option, while minimizing disruptions that can occur when patients transfer between health care facilities.

“Continuous care has been shown to improve outcomes, increase patient satisfaction, lower the risk of hospital readmission and decrease overall health care costs,” Caron said. “We are dedicated to meeting the Dallas area’s need for high-quality, coordinated care that extends beyond the acute phase of recovery.”

Since 1999, Nexus has developed programs to meet the most pressing needs of pediatric patients across the country. Current transitional care programs at Nexus Children’s Hospital – Dallas include Harbor, which provides rehabilitation and ongoing medical care after complex injuries and illnesses, and Rise, which offers rehabilitation and ongoing medical care after brain and spinal cord injury, stroke, and other neurological illnesses and injuries.

“Nexus’ mission has always been to help individuals return to lives of productivity and meaning, wherever they are in their post-acute journey,” Caron said. “Our Dallas campus continues to provide the nationally recognized care Nexus Health Systems is known for, with a special emphasis on pediatric post-acute care.”

Rejuvenate Biomed and SAS Tap AI to Develop Disease-agnostic Drug Repurposing Discovery Tools

Rejuvenate Biomed and SAS announced today a partnership to develop a user-friendly drug repurposing discovery tool for researchers and scientists to uncover medically relevant insights about drugs, diseases, and biological networks, through fast and systematic explorations of hidden biological patterns.

The discovery tool will be developed on SAS® Viya®, a powerful cloud-native artificial intelligence (AI) and data platform. The partnership will unite Rejuvenate Biomed’s clinically validated AI-driven drug discovery platform and end-to-end drug development proficiency with SAS’ decades of AI expertise.

The comprehensive low-code tool will take data from known biomedical relationships and use SAS-based analytics to implement algorithms to uncover non-trivial and novel biological interactions, tapping SAS Visual Analytics for report creation. Aimed at ease of use, the tool will cater to bioscience researchers with limited coding experience, while also serving as a foundation for advanced analytics model development for cutting-edge computational biology teams.

In addition, the collaboration between the two companies equips Rejuvenate Biomed with the tools and technology necessary to further develop and scale up its drug discovery platform, third party services and drug development pipeline.

“Our partnership with SAS amplifies the core strengths of both our R&D teams,” Dr. Ann Beliën, Founder and Chief Executive Officer of Rejuvenate Biomed. “By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities.”

“Our collaboration with Rejuvenate Biomed places us at the forefront of AI in biomedical research, reinforcing our commitment to supporting cutting-edge applied AI and analytics through SAS Viya,” said Udo Sglavo, Vice President of Applied AI and Modeling at SAS. “Rejuvenate Biomed’s endorsement of SAS Viya to further develop their unique and proprietary drug discovery engine is a testament to our commitment to being the premier provider of structured and scalable AI solutions that enhance data analysis efficiency and accelerate the entire drug development life cycle.”

SURGLASSES Announces Successful First Clinical Implementation of Caduceus S AR Surgical Navigation System in Thailand

Surgical Navigation System in Thailand
Associate Professor Prof. Wicharn Yingsakmongkol, M.D. discussing AR products with Min-Liang Wang, CEO.

Leading augmented reality (AR) medical technology company SURGLASSES today announced that, in collaboration with exclusive distributor Goodlifeintertrade.co. Ltd., it has successfully registered and clinically implemented its AR-based Caduceus S surgical navigation system in Thailand. This groundbreaking system is designed to assist various minimally invasive surgeries, significantly enhancing surgical precision and patient outcomes.

The first AR-guided surgery using only the C-arm in Thailand was successfully performed at Thailand Veterans General Hospital by Dr. Chaiyos Chaichankul. The 78-year-old patient had preoperative symptoms of leg numbness, radiating pain, and difficulty walking. After the surgery, the patient’s nerve numbness in the legs disappeared, and the pain was significantly reduced. The day after the surgery, the patient could sit up and walk, and was discharged four days later, resuming work in two weeks. Dr. Chaiyos Chaichankul remarked, “The AR technology of the Caduceus S surgical navigation system allows us to precisely locate and treat the affected area, greatly increasing the success rate of surgeries and accelerating patient recovery.”

Additionally, SURGLASSES completed the first AR-guided surgery combined with O-arm technology at Chulalongkorn Hospital, led by renowned Associate Professor Prof. Wicharn Yingsakmongkol, M.D., and performed by Dr. Vit. The patient, a 48-year-old woman, had a preoperative back pain level of 10 out of 10. Post-surgery, her pain immediately reduced to 4, and two weeks later, it was completely gone. Dr. Vit stated, “Using the Caduceus S system in surgery not only enhances our precision but also shortens patient recovery time. We look forward to utilizing this innovative technology in more surgeries in the future.”

The Caduceus S AR surgical navigation system is an advanced tool specifically designed for augmented reality spine surgery. Through its 3D visualization capabilities, surgeons can clearly view the internal anatomy of patients during procedures, including bones, tissues, and organs, thereby improving surgical accuracy and outcomes. AR minimally invasive spine surgery and spine navigation technology are becoming integral parts of modern healthcare, with SURGLASSES leading the charge in this field.

SURGLASSES CEO Min-Liang Wang commented, “We are thrilled with the significant clinical outcomes achieved by the Caduceus S surgical navigation system in Thailand. We are grateful for the collaboration with Dr. Chaiyos Chaichankul as well as the efforts of our research teams in Taiwan and the US. These successes demonstrate the potential of our technology to enhance the quality of healthcare.”

SURGLASSES is dedicated to addressing the limitations of current medical imaging technology through the use of AR. The Caduceus S system enables clinicians to visualize patients’ internal anatomical structures in 3D during surgery, including bones, tissues, and organs, thereby improving surgical precision and outcomes. The AR navigation technology also allows for future collaboration with remote clinicians through shared visualization and real-time communication, providing guidance during collaborative patient care.

SURGLASSES is an innovative medical technology company with subsidiaries in the US and Taiwan, committed to advancing human health through its AR digital augmented reality ecosystem. The Caduceus S augmented reality visualization platform aims to unlock the full potential of 3D data, transforming image-guided medical procedures through intuitive 3D X-ray visualization. The system has received FDA 510(k) clearance, as well as approvals from Taiwan TFDA and Thailand FDA, and is actively expanding its global market presence.

Through these advanced technologies, SURGLASSES is shaping the future of augmented reality surgical navigation systems, providing medical professionals worldwide with more efficient and precise surgical tools. The successful application of the Caduceus S marks a new era in medical technology, promising better surgical experiences and recovery outcomes for patients around the globe.

Top 4 Tips for Working Out While Pregnant

Working Out While Pregnant

When those two lines first pop up on the pregnancy test, it’s a moment in your life you’ll never forget. What follows is a lot of planning, preparation, and questions— What comes next? What will have to change? What can stay the same?

At the top of the list of priorities for the next nine months is staying physically active. Having a regular workout routine is one of the best ways to stay healthy and feel your best— particularly when you’re pregnant. No matter what your pre-pregnancy activities look like, there are a couple of things you need to keep in mind to ensure you’re exercising safely for you and your baby. Keep reading to see our top tips for expectant moms working out while pregnant.

Whether you were physically active before your pregnancy and want to continue with your current workout routine or you’re someone new to exercise looking to set yourself a routine, you must talk to your doctor, or a midwife who has the requisite qualifications like a direct entry MSN, and get clearance before you start exercising while pregnant.

The Benefits of Exercising While Pregnant

Before we jump into covering our top tips, let’s go through some of the benefits of staying active while pregnant. Having regular exercise as part of your routine during pregnancy can help ease the body into all of the changes it’s going through, as well as prepare the body for childbirth and recovery post-birth.

Exercising throughout your pregnancy offers many physical and emotional benefits, including;

  • Strengthening muscles and joints
  • Reducing back and pelvic pain
  • Reducing stress and anxiety
  • Increasing your energy levels
  • Decreasing the risk of pregnancy complications
  • Fewer complications in delivery
  • Improved postpartum recovery

Tip #1: Find Pregnancy-Safe Exercises

There’s no doubt staying physically active during your pregnancy is good for you. However, you must keep in mind not every exercise will be appropriate. Depending on the trimester you’re in and how you’re feeling generally, the types of exercises you can do will vary.

Some suggested exercise activities that are generally safe and productive to do while you’re pregnant, even for beginners, include;

  • Walking
  • Jogging
  • Yoga and stretching
  • Pilates
  • Swimming
  • Aquarobics

Before starting any exercises, consult a qualified doctor who can provide guidance on safe pregnancy exercises and address any concerns or health conditions you may have.

Tip #2: Avoid Overheating and Stay Hydrated

Ease into each exercise with a five-minute warm-up and always remember to cool down afterwards. While you’re exercising, be aware of the intensity level and make sure you’re not getting too hot. The body’s temperature is higher during pregnancy so doing intensive exercises can cause your core temperature to rise to an unsafe level for your baby. This also means you should avoid strenuous exercise in hot or humid weather.

Going hand-in-hand with avoiding overheating your body is making sure you’re staying hydrated. Drink plenty of water, or other hydrating liquids, before, during, and after exercising to replenish fluids lost from sweating.

Tip #3: Try to Keep Active Daily

Exercising during pregnancy doesn’t mean you have to follow an elaborate workout routine every day of the week— just 30 minutes of walking a day can be enough. Whatever exercise you choose to incorporate into your routine, whether it’s a mixture of yoga, pilates, and aqua aerobics classes or simply going for walks every day, you must be consistent and try to keep active on a daily basis.

If you don’t have enough time to do your exercises all in one go, the good news is that you don’t have to. Break up your exercise routine throughout the day. Remember, any physical activity is better than none!

Tip #4: Listen to Your Body

The physical changes your body goes under when you’re pregnant create extra demands on your body that you shouldn’t ignore. Always listen to your body and adjust any activities or make exercise modifications in your routine accordingly.

Staying active and working out while pregnant is beneficial for both the mom and the baby. Once you’ve consulted a doctor, found pregnancy-safe exercises, and started keeping active daily, make sure you’re always listening to your body and stopping, or making changes, when you feel discomfort or pain.

Stryker’s Spine Guidance 5 Software featuring Copilot receives 510(k) clearance from FDA

Spine Guidance 5 Software
Q Guidance System with Spine Guidance 5 Software featuring Copilot is a first-to-market technology, pioneering new planning and surgical capabilities.

Stryker (NYSE:SYK), a global leader in medical technologies, today announced that its Q Guidance System with Spine Guidance 5 Software featuring Copilot received 510(k) clearance from the U.S. Food and Drug Administration. This first-to-market technology seamlessly integrates smart-powered* instruments into Stryker’s growing ecosystem.

Spine Guidance Software with Copilot’s breakthrough ­technology was built to provide multiple feedback modalities for supporting bone resection, pedicle preparation and screw delivery to help maximize a surgeon’s effectiveness and enhance patient outcomes. Stryker engaged over 850 orthopaedic spine surgeons and neurosurgeons to develop this technology.

“This project is a prime example of our mission in action,” said Dylan Crotty, president of Stryker’s Instruments division. “We listened to our customers’ evolving needs and are engaging leading surgeons to create a product that adds confidence to their workflow.”

Smart Zones for bone resection provide auditory and sensory feedback when surgeons approach the planned boundaries of anatomical alert zones with the high-speed drill. To complement Smart Zones, the Copilot Smart Driver** stops automatically when it reaches the planned depth, supporting surgeon precision during pedicle preparation and screw placement. The automatic depth stop feature is proprietary technology that unlocks only when using a Stryker implant.

“Spine Guidance Software with Copilot is just the beginning of our development pipeline,” said Robbie Robinson, president of Stryker’s Spine division. “While focusing on innovation and the integration of our implants, instrumentation and enabling technologies, we strive to help surgeons perform safe and efficient procedures that enable better patient outcomes.”

The first clinical cases using Spine Guidance Software with Copilot will begin in September, with a full commercial launch expected later this fall. For more information on Spine Guidance Software with Copilot please visit https://www.stryker.com/us/en/nse/products/spine-guidance-software-copilot.html.

*Smart features enabled by the Q Guidance System with Spine Guidance 5 Software.
**SPINE-COP-BROC-1169302

Atraverse Medical Announces First Clinical Use of HOTWIRE™ Radiofrequency (RF) Guidewire System at St. Bernards Medical Center

Atraverse Medical
HOTWIRE™ RF guidewire by Atraverse Medical

Atraverse Medical HOTWIRE™ RF guidewire device has been used for the first time in clinical practice by world-renowned cardiac electrophysiologist, Dr. Devi Nair, at St. Bernards Medical Center. The best-in-class left-heart access device received FDA 510(k) clearance earlier this year and was unveiled at the Heart Rhythm Society congress in May.

Co-founded by Dr. Steven Mickelsen, the pioneer of Farapulse pulsed field ablation technology, Atraverse’s HOTWIRE™ device is a novel radiofrequency (RF) guidewire that enables zero exchange left-heart access while acting as a rail for catheter-based therapy systems. Featuring universal sheath compatibility, the HOTWIRE™ is designed to improve patient outcomes and streamline procedural workflows.

“We are thrilled to use the HOTWIRE™ in our clinical practice and are proud to be first in the world to utilize this innovative technology,” commented Dr. Nair, who performed twelve cases after crossing the septum with the HOTWIRE™, including four atrial fibrillation ablation procedures and eight left atrial appendage closures, while utilizing five different models of transseptal sheaths. “We have been eagerly awaiting a sheath-agnostic solution like this, and we look forward to using the product in a majority of our cases going forward for left atrial access.”

Eric Sauter, COO and Co-Founder for Atraverse Medical, commented…

“Our mission is to improve efficiency and take the guesswork out of what should be simply-executed therapeutic and diagnostic procedures. Our collaboration with Dr. Nair exemplifies our dedication to taking patient care to the next level with innovative technologies.”

In addition, the company has strengthened its executive leadership team with two industry veterans in support of its commercialization plan. Jay Kelley, MBA, who joined the Atraverse Medical team as Vice President of Marketing in 2023, has been promoted to Chief Marketing Officer.  Mr. Kelley has been instrumental in the development of Atraverse’s commercialization strategy to drive market adoption with a focused launch. He has more than 20 years of medical device R&D and commercialization experience, primarily focused on cardiac electrophysiology.

Most recently, in May of 2024, Brandon Allen joined Atraverse as Vice President of Sales.  Mr. Allen brings two decades of experience in the cardiac electrophysiology space, serving with market leaders including Biosense and Guidant / Boston Scientific, and has propelled the company forward following the FDA 510(k) clearance of the HOTWIRE™.

“Our HOTWIRE™ device has gained the attention of several thought leaders in the field, and we are excited to have Jay and Brandon on the team leading commercialization efforts,” noted John Slump, CEO and Co-Founder of Atraverse Medical. “Their deep experience and impeccable reputations are a tremendous asset to our company.”

Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures

Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company focused on reducing the risk and impact of stroke, today announced the milestone that more than 100,000 TCAR procedures have been performed to date.

Since its inception, Silk Road has worked diligently to reduce the risk of stroke during treatment of carotid artery disease through innovative technology and minimally invasive techniques. Silk Road is credited with pioneering the TCAR procedure and building the ENROUTE® Transcarotid Neuroprotection System (ENROUTE NPS) that supports the procedure with its patented flow reversal technology. Compared to traditional open surgery (carotid endarterectomy or “CEA”), TCAR has demonstrated a lower risk of acute heart attack, less occurrences of nerve injury, shorter time required to perform the procedure, and a reduced length of stay at the hospital for patients.

“A growing number of patients come to us looking for a solution that is minimally invasive and requires less downtime so they can get back to their daily lives,” said Dr. Gregg Landis, System Chief of Vascular Surgery at Northwell Health. “It’s incredible that Silk Road was able to not only address that need by creating the TCAR procedure, but also achieve such widespread adoption in a short period of time. TCAR has transformed the way we approach treating carotid artery disease while consistently delivering positive patient outcomes.”

Every year, 15 million people worldwide suffer a stroke and carotid artery disease is attributed to more than 800,000 strokes in U.S. patients each year. The growing prevalence of carotid artery disease further reinforces the need for a more efficient, effective and scalable approach to stroke prevention.

“Completing the 100,000th TCAR procedure is the culmination of more than 15 years’ worth of work by members of the Silk Road Medical team and the healthcare providers we work with,” said Chas McKhann, CEO of Silk Road. “As we celebrate this important milestone, we remain excited and motivated to establish TCAR as the standard of care for addressing carotid artery disease.”

To hear more from physicians and patients on how TCAR is enabling Brighter Tomorrows, visit: https://silkroadmed.com/100K

About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in patients at high risk and standard risk for complications from CEA, in conjunction with the ENROUTE NPS during the TCAR procedure. The ENROUTE NPS is a first in class device used to directly access the common carotid artery and initiate high-rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.

Alexandrite Lasers vs. IPL: Which Is Better for Your Practice

lasers

So, you’re in the market for some hair removal technology and find yourself weighing Alexandrite lasers against Intense Pulsed Light (IPL) systems. It’s a common crossroad for many practices looking to enhance their aesthetic services. Both options have their fans, but the best choice really depends on what your practice needs and the kinds of results your clients expect.

Let’s dive into what makes each technology tick, and how choosing the right used aesthetic laser or IPL system could make all the difference in how your practice performs. Ready to figure out which one will be your new go-to?

Alexandrite Lasers: Precision for Hair Removal

Thinking about adding an Alexandrite laser to your practice? Great choice! These lasers are pretty much the gold standard for hair removal. Why? Well, they’re tuned to a specific wavelength of 755 nm, which is just the right frequency to target melanin in the hair follicles effectively.

Here’s a quick rundown on why an Alexandrite laser might just be the perfect addition to your toolkit:

  • Targeted Efficacy: When it comes to precision, Alexandrite lasers are top-notch. They’re especially good for clients with lighter to olive skin tones, ensuring that hair removal is not only effective but also precise.
  • Speed and Efficiency: Looking to zap through appointments quicker? Alexandrite lasers work fast, allowing you to treat large areas in less time. This means you can boost patient throughput without sacrificing quality.
  • Best for Lighter Skin Tones: If a lot of your clients have lighter skin, this laser is ideal. It’s designed to minimize the risk of pigmentation changes, making it a safe option for these skin types.

IPL Systems: Versatility Across Skin Treatments

Are you looking to ramp up your practice’s skin care services? If so, IPL (Intense Pulsed Light) technology might just be what you need. What’s so cool about IPL? It uses a broad spectrum of light to tackle a whole bunch of skin issues. This means you can offer a wide range of treatments all with just one machine. Here’s why IPL systems are such a hit:

  • Wide Range of Applications: Whether it’s zapping away unwanted hair, fading age spots, tackling vascular lesions, or smoothing out those signs of aging, IPL systems have you covered. Their ability to handle multiple skin concerns makes them a versatile powerhouse in any practice.
  • Customizable Treatments: Every client is unique, right? With IPL, you can switch up filters to tailor treatments to each person’s specific skin type and condition. This customization helps ensure better results and happier clients.
  • A Gentler Approach: If you have clients with sensitive skin, they might be a bit wary of laser treatments. IPL offers a gentler alternative that’s often just as effective, which could be a big relief for those sensitive folks.

So, if you’re aiming to be a one-stop-shop for skin care, an IPL system might be the versatile tool you need to keep your clients looking and feeling great.

Choosing What’s Best for Your Practice

The decision between purchasing an Alexandrite laser for sale and an IPL system boils down to your practice’s specific needs:

  • Consider Your Clientele: Assess the common skin types and conditions you treat. If your practice sees a high volume of hair removal patients with lighter skin, Alexandrite laser for sale could be more beneficial. For a wider range of skin conditions, IPL might offer the flexibility you need.
  • Evaluate Treatment Goals: Determine whether your focus is on specialized treatments like hair removal or broader skin care solutions.
  • Factor in Cost vs. Return: While Alexandrite lasers might offer faster treatments for specific conditions, IPL systems provide a broader range of services. Consider which option offers the best return on investment for your practice.

Thinking About Leveling Up Your Practice’s Tools?

Whether you’re leaning towards the precision of an Alexandrite laser or the versatility of an IPL system, choosing the right used aesthetic laser is a crucial decision that can significantly enhance your service offerings. At Used Aesthetic Lasers Pro, we’re here to help you make that choice with confidence.

If you’re unsure which type of laser will best suit your needs or if you just want more information, don’t hesitate to get in touch. Our friendly experts are ready to walk you through the options and help you weigh the benefits, ensuring you feel confident and informed.

Why not take the next step in enhancing your service offerings? Contact us today, and let’s explore how our used aesthetic lasers can help you achieve the exceptional results your clients expect. Upgrading your practice could be just one conversation away!

 

1...252627...923Page 26 of 923

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330